Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effects of Different Doses of Caffeine on Physical and Cognitive Performance in Female Handball Players

24 april 2026 bijgewerkt door: Ulaş Can YILDIRIM, Sinop University

Dose-Dependent Effects of Acute Caffeine Ingestion on Physical and Cognitive Performance in Female Handball Players: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

This study investigates how different doses of caffeine affect physical and cognitive performance in female handball players. Caffeine is widely used as a performance-enhancing substance, but its effects may vary depending on the type of performance and the dose consumed.

In this randomized, double-blind, placebo-controlled crossover study, participants complete three experimental conditions: placebo, low-dose caffeine (3 mg/kg), and moderate-dose caffeine (6 mg/kg). Each participant receives all conditions in a randomized order, with sufficient time between sessions to avoid carryover effects.

The study evaluates three main performance domains relevant to team sports. Physical performance is assessed using an intermittent running test. Cognitive performance is measured using a reaction time task that evaluates attention and inhibitory control. In addition, a throwing test is used to assess sport-specific motor performance.

The main objective is to determine whether caffeine produces dose-dependent improvements and whether these effects differ across physical, cognitive, and technical performance domains. The findings aim to provide practical insights for athletes and coaches regarding optimal caffeine use in team sport settings.

Studie Overzicht

Gedetailleerde beschrijving

Caffeine is one of the most widely consumed ergogenic aids in sport, known to influence both physiological and cognitive processes primarily through antagonism of adenosine receptors. Although its beneficial effects on endurance performance and alertness are well established, evidence regarding its effects on cognitive control and sport-specific technical skills remains inconsistent, particularly in team sport settings where multiple performance domains interact.

Team sports such as handball require the integration of intermittent high-intensity physical efforts, rapid decision-making, and precise motor execution. These components are not independent; instead, they compete for shared neurocognitive resources, especially under conditions of fatigue. As a result, interventions such as caffeine supplementation may exert domain-specific effects rather than uniform improvements across all aspects of performance.

Despite extensive research on caffeine, most studies have examined either physical or cognitive outcomes in isolation. Furthermore, dose-response relationships remain unclear, with previous findings suggesting that lower doses may be sufficient to enhance physical performance, whereas cognitive outcomes may require higher levels of stimulation. However, limited evidence exists on whether these dose-dependent effects are maintained when multiple performance domains are assessed within the same experimental framework.

The present study addresses this gap by simultaneously evaluating physical, cognitive, and sport-specific motor performance following different doses of caffeine in female handball players. A randomized, double-blind, placebo-controlled crossover design is used to minimize inter-individual variability and improve internal validity. Participants complete three experimental conditions (placebo, low-dose caffeine, and moderate-dose caffeine), each separated by an adequate washout period to reduce potential carryover effects.

The protocol includes standardized procedures to control for confounding factors such as time of day, environmental conditions, and prior physical activity. Testing sessions follow a fixed sequence, beginning with cognitive assessment, followed by a sport-specific throwing task, and concluding with an intermittent running test. This structure is designed to reflect the multi-component demands of team sport performance while maintaining methodological control.

The primary objective is to determine whether caffeine produces dose-dependent effects across different performance domains. Specifically, the study examines whether physical performance improvements occur at lower doses, whether cognitive performance shows greater sensitivity to higher doses, and whether technical motor performance responds differently to caffeine ingestion. By integrating these domains within a single experimental design, the study aims to provide a more ecologically valid understanding of caffeine's ergogenic effects in team sport contexts.

The findings are expected to contribute to evidence-based recommendations for caffeine use in athletes, emphasizing the importance of aligning supplementation strategies with specific performance goals rather than assuming uniform benefits across all domains.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

20

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Female handball players
  • Regular participation in competitive handball training
  • Minimum of 3 years of handball training experience
  • Free from musculoskeletal injury within the past 6 months

Exclusion Criteria:

  • Known caffeine sensitivity or allergy
  • Use of medications or supplements that may affect physical or cognitive performance
  • Presence of cardiovascular disease
  • Presence of metabolic disorders

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Placebo-vergelijker: Placebo Condition
Participants receive placebo capsules prior to testing in a randomized
Ingestion of identical capsules containing polydextrose with no active ingredient, administered 60 minutes prior to testing.
Experimenteel: Low-Dose Caffeine
Participants receive 3 mg/kg caffeine prior to testing in a randomized
Acute ingestion of caffeine at a dose of 3 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.
Experimenteel: Moderate-Dose Caffeine
Participants receive 6 mg/kg caffeine prior to testing in a randomized
Acute ingestion of caffeine at a dose of 6 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Flanker Task Reaction Time
Tijdsspanne: During each experimental session (60 minutes after supplementation)
Mean reaction time (ms) during correct trials in the Simplified Eriksen Flanker task, used to assess cognitive processing speed.
During each experimental session (60 minutes after supplementation)
Yo-Yo Intermittent Recovery Test Level 1 Distance
Tijdsspanne: During each experimental session (60 minutes after supplementation)
Total distance covered during the Yo-Yo Intermittent Recovery Test Level 1, used to assess intermittent running performance.
During each experimental session (60 minutes after supplementation)
Throwing Velocity
Tijdsspanne: During each experimental session (60 minutes after supplementation)
Mean ball velocity (km/h) measured during a standardized handball throwing test.
During each experimental session (60 minutes after supplementation)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Flanker Task Accuracy
Tijdsspanne: During each experimental session (60 minutes after supplementation)
Percentage of correct responses in the Simplified Eriksen Flanker task.
During each experimental session (60 minutes after supplementation)
Flanker Effect
Tijdsspanne: During each experimental session (60 minutes after supplementation)
Difference in reaction time between incongruent and congruent trials in the Flanker task.
During each experimental session (60 minutes after supplementation)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 januari 2026

Primaire voltooiing (Werkelijk)

10 maart 2026

Studie voltooiing (Werkelijk)

20 maart 2026

Studieregistratiedata

Eerst ingediend

24 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

24 april 2026

Eerst geplaatst (Werkelijk)

1 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

24 april 2026

Laatst geverifieerd

1 april 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

At the time of registration, a decision regarding sharing individual participant data (IPD) has not yet been finalized. The study dataset is currently being prepared for publication and institutional archiving. Future data sharing will be considered after publication, taking into account institutional policies, ethical approvals, and participant confidentiality requirements. If appropriate, de-identified data underlying the published results may be made available upon reasonable request.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren